Montelukast Sodium Market Valued to Reach USD $5.89 Billion by 2029 at 8.8% CAGR

 Save 20% on All Global Market Reports With Code ONLINE20 — Gain Insights Into Tariffs, Inflation, and Industry Trends

 

 What Will Be the Forecast Market Size of the Global Montelukast Sodium Market by 2029?
 The montelukast sodium market size has grown strongly in recent years. It will grow from $3.86 billion in 2024 to $4.2 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to increasing respiratory disorders, an aging population, rising air pollution levels, growing awareness and education, and expansion in emerging markets.
 
 The montelukast sodium market size is expected to see strong growth in the next few years. It will grow to $5.89 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to approval and launch, clinical studies, patent expiry, regulatory changes, and physician prescribing patterns. Major trends in the forecast period include increased generic competition, a shift towards combination therapies, expansion in emerging markets, a focus on pediatric use, and digital health solutions.
 
 Claim your free report sample now:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=16123&type=smp
 
 What Are the Leading Growth Factors in the Montelukast Sodium Market?
 The increasing prevalence of asthma is expected to propel the growth of montelukast sodium market going forward. Asthma is a chronic respiratory disorder marked by inflammation and constriction of the airways, resulting in repeated bouts of wheezing, breathlessness, chest tightness, and coughing. The prevalence of asthma is increasing due to environmental pollution, allergen exposure, genetic predisposition, urbanization, changes in lifestyle, and respiratory infections. Montelukast sodium is used in asthma as a leukotriene receptor antagonist, helping to prevent and manage asthma symptoms by blocking the action of leukotrienes, which contribute to airway inflammation and constriction. For instance, in July 2024, according to the American Lung Association, a US-based voluntary health organization, in 2022, approximately 44.2 million Americans, or 13.5% of the population, had been diagnosed with asthma by a healthcare professional. Therefore, the increasing prevalence of asthma is driving the growth of montelukast sodium market.
 
 Which Segment Offers the Highest Growth Opportunities in the Montelukast Sodium Market?
 The montelukast sodium market covered in this report is segmented — 
 
 1) By Product: Crystal-like, Form-less Or Amorphous
 2) By Dosage Form: Tablets, Oral Solutions
 3) By Application: Bronchospasm, Allergic Coryza, Asthma, Urticaria, Other Applications
 
 Subsegments:
 1) By Crystal-Like: Monohydrate Crystal, Anhydrous Crystal, Spherical Crystals, Needle-Like Crystals, Polycrystalline Montelukast Sodium 
 2) By Form-Less Or Amorphous: Amorphous Powder, Amorphous Granules, Non-Crystalline Montelukast Sodium
 
 
 Which Trends Are Positively Affecting the Montelukast Sodium Market Expansion?
 Major companies operating in the montelukast sodium market are developing new drugs such as over-the-counter generic medication to provide more convenient treatment options for patients managing asthma and allergic rhinitis. Over-the-counter (OTC) generic medications are drugs that can be bought without a prescription, usually found in pharmacies or retail stores. For instance, in July 2022, Dr. Reddy’s Laboratories, an India-based pharmaceutical company launched Fexofenadine HCL 180 mg and Pseudoephedrine HCl 240 mg in the US. This medication is designed for the temporary relief of nasal and sinus congestion due to colds or allergies. It is equivalent to Allegra-D 24 HR, it combines an antihistamine and nasal decongestant to alleviate symptoms such as sneezing, runny nose, itchy eyes, and throat. Available in 5, 10, and 15-count pack sizes, it offers a high-quality, cost-effective solution for those seeking relief from upper respiratory discomfort. 
 
 Who Are the Leading Companies in the Montelukast Sodium Industry by Revenue?
 Major companies operating in the montelukast sodium market are Pfizer Inc., Merck & Co. Inc., Sanofi Aventis SA, Teva Pharmaceuticals USA Inc., Hetero Labs Ltd., Sun Pharma Industries Ltd., Aurobindo Pharma Limited, Cipla Inc., Intas Pharmaceuticals Ltd., Seqens Group, Sanyo Chemical Industries Ltd., Morepen Laboratories, Neuland Laboratories Ltd., Medopharm Private Ltd., BEC Chemicals Pvt. Ltd, Delmar Chemicals Inc., Kimia Biosciences Ltd., Ortin Laboratories Ltd., MSN Laboratories Pvt Ltd., Vamsi Labs Ltd., LGM Pharma LLC, HRV Global Life Sciences, Sigmak Lifesciences, Akums Lifesciences Ltd., Anwita Drugs & Chemicals Pvt Ltd
 
 Get the full montelukast sodium market report here:
 https://www.thebusinessresearchcompany.com/report/montelukast-sodium-global-market-report
 
 What Are the Regional Opportunities for Investment in the Montelukast Sodium Market?
 North America was the largest region in the montelukast sodium market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the montelukast sodium market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company